An excellent analysis of the AstraZeneca pipeline performance was recently published in Nature Review. The objective of this study was to identify and assess key factors which drive R&D performance:…
Yesterday the Wall Street Journal summarized the current situation in antibiotic drug development and commercialization. To summarize: Big Pharma is slowly returning to antibiotic (really, antibacterial) drug discovery…
How much does it cost to develop an approved drug? We may never know, but Matt Herper from Forbes takes an interesting approach to come up with some estimates.
In a surprise decision last week, the US FDA decided to approve Brisdelle, a low-dose formulation of paroxetine, for the treatment of menopausal hot flashes. This comes on…
Oramed announced last week that their oral insulin capsule is ready for Phase II trials in the US: Oramed's ORMD-0801 is an orally ingestible insulin capsule indicated for…
In 1941, Let Us Now Praise Famous Men was published. This unusual book is an account of Southern sharecroppers in the Deep South in 1936. It is a difficult…
Yesterday, North Carolina-based Pozen gave a detailed Investor Update, focused on PA32540, a "Coordinated-Delivery Tablet Containing Enteric-Coated Aspirin and Immediate-RElease Omeprazole." Information on the company's pipeline is available…
Very interesting point made by Ranjit Shahani from Novartis India: The immense talents in India's pharmaceutical companies should be focused on R&D of medicines that will help the people…
At Lacerta Bio, we've been reading the fascinating book, The Signal and The Noise by Nate Silver. The book is a terrific review of how and why forecasts often fail,…
The always excellent Bruce Booth wrote a good summary of the key Preclinical deals we've seen so far this year. The post is available here. Some of his broader questions are especially…